Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer.
AffiliationUCD School of Medicine and Medical Science, University College Dublin, UCD, Belfield, Dublin 4, Ireland; UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Dublin 4, Ireland; National Cancer Control Programme, King's Inns House, Dublin 1, Ireland. Electronic address: Barbara.firstname.lastname@example.org.
Local subject classificationCANCER, OVARIAN
M Phase Cell Cycle Checkpoints
Neoplasm Recurrence, Local
MetadataShow full item record
CitationMcGrogan B et al. Spindle assembly checkpoint protein expression correlates with cellular proliferation and shorter time to recurrence in ovarian cancer. Hum. Pathol. 2014, 45 (7):1509-19
AbstractOvarian carcinoma (OC) is the most lethal of the gynecological malignancies, often presenting at an advanced stage. Treatment is hampered by high levels of drug resistance. The taxanes are microtubule stabilizing agents, used as first-line agents in the treatment of OC that exert their apoptotic effects through the spindle assembly checkpoint. BUB1-related protein kinase (BUBR1) and mitotic arrest deficient 2 (MAD2), essential spindle assembly checkpoint components, play a key role in response to taxanes. BUBR1, MAD2, and Ki-67 were assessed on an OC tissue microarray platform representing 72 OC tumors of varying histologic subtypes. Sixty-one of these patients received paclitaxel and platinum agents combined; 11 received platinum alone. Overall survival was available for all 72 patients, whereas recurrence-free survival (RFS) was available for 66 patients. Increased BUBR1 expression was seen in serous carcinomas, compared with other histologies (P = .03). Increased BUBR1 was significantly associated with tumors of advanced stage (P = .05). Increased MAD2 and BUBR1 expression also correlated with increased cellular proliferation (P < .0002 and P = .02, respectively). Reduced MAD2 nuclear intensity was associated with a shorter RFS (P = .03), in ovarian tumors of differing histologic subtype (n = 66). In this subgroup, for those women who received paclitaxel and platinum agents combined (n = 57), reduced MAD2 intensity also identified women with a shorter RFS (P < .007). For the entire cohort of patients, irrespective of histologic subtype or treatment, MAD2 nuclear intensity retained independent significance in a multivariate model, with tumors showing reduced nuclear MAD2 intensity identifying patients with a poorer RFS (P = .05).
- Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30.
- Authors: Fu Y, Ye D, Chen H, Lu W, Ye F, Xie X
- Issue date: 2007 Apr
- Clinicopathologic significance of BubR1 and Mad2 overexpression in oral cancer.
- Authors: Teixeira JH, Silva P, Faria J, Ferreira I, Duarte P, Delgado ML, Queirós O, Moreira R, Barbosa J, Lopes CA, do Amaral JB, Monteiro LS, Bousbaa H
- Issue date: 2015 Sep
- Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.
- Authors: Bargiela-Iparraguirre J, Prado-Marchal L, Pajuelo-Lozano N, Jiménez B, Perona R, Sánchez-Pérez I
- Issue date: 2014
- MAD2 expression in oral squamous cell carcinoma and its relationship to tumor grade and proliferation.
- Authors: Rizzardi C, Torelli L, Schneider M, Giudici F, Zandona L, Biasotto M, Di Lenarda R, Melato M
- Issue date: 2014 Dec
- Expression of the mitotic-arrest deficiency 2 is associated with chemotherapy resistance in ovarian serous adenocarcinoma.
- Authors: Nakano Y, Sumi T, Teramae M, Morishita M, Fukuda T, Terada H, Yoshida H, Matsumoto Y, Yasui T, Ishiko O
- Issue date: 2012 Oct